N.v. Nutricia

Gelske Speelmans

Eline Marleen Van Der Beek

Jan Knol

Martine Sandra Alles

Renate Maria Louise Zwijsen

Maria Johanna Adriana Petronella Govers

Günther Boehm

Marieke Abrahamse-Berkeveld

Adrianus Johannes Maria Vriesema

Annemiek Lidewij Schipper

Robert Johan Joseph Hageman

Johan Garssen

Christopher Beermann

Antonie Van Baalen

Willem Ferdinand Nieuwenhuizen

Annemarie Oosting

Eric Alexander Franciscus Van Tol

Monique Haarman

Marieke Abrahamse-Berkenveld

Renate Maria Louise Zwijssen

Kaouther Ben Amor

Eric Alexander Fransiscus Van Tol

The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes.

Infant nutrition for improving fatty acid composition of brain membranes

The present invention relates to the field of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).

Synergism of GOS and polyfructose

A composition comprising, a non-digestible saccharide A and a non-digestible saccharide B, optionally combined withand the use of said composition for the treatment and/or prevention of gastro-intestinal disorder, immune disorder and/or endocrine disorder.

Nutritional composition with probiotics

The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic and alpha-linolenic acid.

Infant nutritional compositions for preventing obesity

The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a lipid globules coated with phospholipids. The composition is used for increasing bone mineral content, bone mineral density, preventing osteoporosis, and/or preventing ostopenia.

Nutritional compositions with coated lipid globules

The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant between 0 and 36 months of age.

The present invention relates to a composition to a nutritional composition comprising 0.1 to 15 gram fermentable partially hydrolysed gum having a degree of polymerization between 10 and 300 per 100 gram dry weight of the composition and 0.1 to 15 gram fermentable, indigestible polysaccharide other than a hydrolysed gum having a DP between 10 and 300 per 100 gram dry weight of the composition.

Composition containing fermantable polysaccharides

The invention relates to a liquid nutrition comprising short chain fatty acyl chains and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and/or prevention of gut barrier related disorders.

Nutrition with lipids and non-digestible saccharides

The invention relates to a liquid nutrition comprising short chain fatty acyl chains, polyunsaturated fatty acyl chains, vegetable oil and a non-digestible, fermentable saccharide. The composition is particular suitable for use as an infant nutrition. The composition is also suitable for treatment and/or prevention of gut barrier related disorders.

The present invention relates to a composition to a nutritional composition comprising 0.1 to 15 gram fermentable e partially hydrolysed gum having a degree of polymerization between 10 and 300 per 100 gram dry weight of the composition and 0.1 to 15 gram fermentable, indigestible polysaccharide other than a hydrolysed gum having a DP between 10 and 300 per 100 gram dry weight of the composition.

Composition containing fermentable polysaccharides

The present invention relates to an enteral composition containing phospholipids, triglycerides and cholesterol or precursors thereof, which can be used in the treatment of sepsis. With the composition of the invention the natural level of chylomicrons is maintained, in particular in gut associated lymphoid tissue (GALT), which ensures that most of LPS and/or LTA which are released in the body can be neutralized, substantially decreasing the risk of locally occurring high levels of LPS and/or LTA and thus sepsis.

Growing community of inventors

Wageningen, Netherlands

Gelske Speelmans